Department of Pathology, University of Utah, 15 N Medical Dr. East Ste. 1100, Salt Lake City, UT 84112, USA; ARUP Institute for Clinical and Experimental Pathology, 500 Chipeta Way, Salt Lake City, UT 84108, USA.
J Immunol Methods. 2022 Nov;510:113350. doi: 10.1016/j.jim.2022.113350. Epub 2022 Sep 5.
Diagnostic vaccination is an integral component in the evaluation of patients suspected to have a B cell or humoral deficiency. Evaluation of antibody production in response to both protein- and polysaccharide-based vaccines aids in distinguishing between specific categories of humoral deficiency. Although assessment of pneumococcal polysaccharide responses is widely available and included in diagnostic guidelines, significant variability still exists in the measurement and interpretation of these responses. Interpretation can also be complicated by age, vaccination history and treatment with immunoglobulin replacement therapy. Despite the challenges and limitations of evaluating pneumococcal polysaccharide vaccine responses, it can provide valuable diagnostic and prognostic information to guide therapeutic intervention. Future efforts are needed to further standardize measurement and interpretation of pneumococcal antibody responses to vaccination and to identify and establish other methods and/or vaccines as alternatives to pneumococcal vaccination to address the challenges in certain patient populations.
诊断性疫苗接种是评估疑似 B 细胞或体液缺陷患者的一个重要组成部分。评估针对蛋白和多糖疫苗的抗体产生情况有助于区分不同类型的体液缺陷。尽管针对肺炎球菌多糖的反应评估已广泛应用于临床并被纳入诊断指南中，但在这些反应的测量和解释方面仍然存在显著的差异。解释也可能受到年龄、疫苗接种史和免疫球蛋白替代治疗的影响。尽管评估肺炎球菌多糖疫苗反应存在挑战和限制，但它可以提供有价值的诊断和预后信息，以指导治疗干预。未来需要进一步努力，以进一步标准化对肺炎球菌抗体反应的测量和解释，并确定和建立其他方法和/或疫苗作为肺炎球菌疫苗接种的替代品，以解决某些患者群体中存在的挑战。
